Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CCFSC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-DNA mimic 4
|
|||||
| Synonyms |
Trastuzumab 16-mer DNA mimic 4
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Q Pho-DNA mimics
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Diphenyltio-Mal-Cap
|
Linker Info | ||||
| Conjugate Type |
ADC was obtained by complete reduction (TCEP) of all four interchain disulfide bridges followed by a site-specific bioconjugation reaction via a diphenylthio-Mal-Cap linker.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.